1. Asahi Shimbun (2013, June 29). Too much of a rush for clinical trials with iPS cells (editorial). Retrieved June 30, 2013, from
http://ajw.asahi.com/article/views/AJ201306280044
.
2. Bayon, Y., Ellis, S., Vertes, A., Ahmed, A., Coury, A. J., Campion, C., et al. (2013). Commercialization of regenerative products—The academic/industry partnership—Society World Congress: Summary report: Vienna, Austria/September 5–8, 2012. Tissue Engineering. Part B, Reviews. doi:
10.1089/ten.TEB.2012.0683
.
3. Bergman, K., & Graff, G. D. (2007). The global stem cell patent landscape: Implications for efficient technology transfer and commercial development. Nature Biotechnology, 25(4), 419–424.
4. Brock, D. (2010). Creating embryos for use in stem cell research. The Journal of Law, Medicine & Ethics, 38(2), 229–237.
5. Bubela, T. M., & Caulfield, T. (2010). Role and reality: Technology transfer at Canadian universities. Trends in Biotechnology, 28(9), 447–451.